Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age
Open Access
- 21 October 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Genomics
- Vol. 1 (1), 52
- https://doi.org/10.1186/1755-8794-1-52
Abstract
Glioblastomas are the most common primary brain tumour in adults. While the prognosis for patients is poor, gene expression profiling has detected signatures that can sub-classify GBMs relative to histopathology and clinical variables. One category of GBM defined by a gene expression signature is termed ProNeural (PN), and has substantially longer patient survival relative to other gene expression-based subtypes of GBMs. Age of onset is a major predictor of the length of patient survival where younger patients survive longer than older patients. The reason for this survival advantage has not been clear. We collected 267 GBM CEL files and normalized them relative to other microarrays of the same Affymetrix platform. 377 probesets on U133A and U133 Plus 2.0 arrays were used in a gene voting strategy with 177 probesets of matching genes on older U95Av2 arrays. Kaplan-Meier curves and Cox proportional hazard analyses were applied in distinguishing survival differences between expression subtypes and age. This meta-analysis of published data in addition to new data confirms the existence of four distinct GBM expression-signatures. Further, patients with PN subtype GBMs had longer survival, as expected. However, the age of the patient at diagnosis is not predictive of survival time when controlled for the PN subtype. The survival benefit of younger age is nullified when patients are stratified by gene expression group. Thus, the main cause of the age effect in GBMs is the more frequent occurrence of PN GBMs in younger patients relative to older patients.Keywords
This publication has 20 references indexed in Scilit:
- Long-term survival with glioblastoma multiformeBrain, 2007
- Lessons learned in the development of targeted therapy for malignant gliomasMolecular Cancer Therapeutics, 2007
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell, 2006
- Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human GlioblastomaJournal of Neuropathology and Experimental Neurology, 2005
- The molecular epidemiology of gliomas in adultsNeurosurgical Focus, 2005
- Gene Expression Profiling and Genetic Markers in Glioblastoma SurvivalCancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Gene Expression Profiling of Gliomas Strongly Predicts SurvivalCancer Research, 2004
- Gene expression profiling identifies molecular subtypes of gliomasOncogene, 2003
- Identification of molecular subtypes of glioblastoma by gene expression profilingOncogene, 2003